While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
In a week during which 23andMe showed results from a clutch of its research programs at the American Society of Human Genetics annual meeting, it also tasked an industry veteran with winning new partnerships.
Microsoft has taken a lead from its co-founder Bill Gates' philanthropic efforts. The computing giant is making its Azure cloud platform available to Ebola researchers who need help with the storage and analysis of data.
Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.
The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
The genetic research community is about to get access to a lot of data. On October 20, two public databases generated by whole-genome and exome sequencing at multiple research institutions will be unveiled.
Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.
Increased reliance on software to support aspects of drug development has simplified many tasks but created the possibility that an IT glitch could have far-reaching implications. Now, the European Medicines Agency is to discuss whether this situation has already happened.
The National Institutes of Health has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding.
The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.
With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.
Accenture has joined with some big names for its R&D analytics platform. Eisai, Merck and Pfizer have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and Oracle.
The Office of the National Coordinator for Health IT published its annual report on the adoption and use of electronic health records.
Another incubator is ready to test Y Combinator's theory that it is possible to get a biotech-related startup off the ground with smaller sums of money than ever before. VC shop SOS Ventures is offering startups working broadly in biology $35,000 in seed funding, mentors and lab space at incubators in San Francisco and Cork, Ireland.
The National Institutes of Health has kicked off the BRAIN Initiative by awarding $46 million to 58 projects. And Google has come on board as a commercial partner to develop software and infrastructure to handle the petabyte-scale data sets the projects are expected to generate.
The explosion in online discussions about medicines and the rise of social-listening tools to mine and analyze the data have given drugmakers another way to learn what patients think about their products. But pharma companies aren't the only ones listening. Wall Street has its ear to the digital grapevine, too.
Reuters reports that Facebook is considering setting up patient support communities and has met with people in the medical industry to discuss its plans.
After years of debate and a late controversy, the European Medicines Agency has adopted a clinical trial transparency policy that will come into force on January 1. And unlike a recent draft of the policy, the final version allows researchers to download the data.
The Patient-Centered Outcomes Research Institute has handed out another tranche of funding, bringing its total awards up to $671 million. Among the recipients of the most recent $102 million are projects to improve the use of electronic health records in comparative-effectiveness research and develop data analysis tools that preserve patient privacy.